Prelude Therapeutics vs Xilio Therapeutics
PRLD and XLO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PRLD and XLO compare
Prelude Therapeutics is the larger company, worth 5.9 times as much as Xilio Therapeutics ($275M against $46.7M).
Prelude Therapeutics grew revenue faster over the last twelve months (220% versus 73.0% for Xilio Therapeutics).
Xilio Therapeutics keeps more of each dollar of sales as profit, with a net margin of −20.9% compared with −270% at Prelude Therapeutics.
Xilio Therapeutics scores higher on the StockData Score (11 against 7 for Prelude Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PRLD | XLO |
|---|---|---|
| Size and price | ||
| Market cap | $275M | $46.7M |
| Share price | $3.45 | $8.07 |
| Change, 1 year | 135% | −25.4% |
| Change, 5 years | −76.1% | −97.5% |
| Beta (5Y) | 1.22 | 0.89 |
| Employees | 79 | 76 |
| StockData Score | ||
| Total score | 7 | 11 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 0 | 2 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 12.3× | 0.8× (better) |
| P/B | 2.1× | 0.7× (better) |
| FCF yield | −12.1% (better) | −123% |
| Fair value | $2.06 | $31.67 |
| Margin of safety | −67.1% | 74.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 220% (better) | 73.0% |
| Profitability | ||
| Operating margin | −301% | −74.9% (better) |
| Net margin | −270% | −20.9% (better) |
| FCF margin | −148% | −105% (better) |
| Return on equity | −57.7% | −38.2% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.07 | 4.72 (better) |
| Altman Z-score | −2.58 (better) | −3.87 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 62.2% | 58.9% |
| Held by insiders | 40.5% | – |
| Insider net buying, 12 months | $25.0M (better) | $38.3K |
| Short interest, % of float | 8.8% | – |
Go deeper
- PRLD stock overview
- PRLD income statement
- PRLD valuation and score
- XLO stock overview
- XLO income statement
- XLO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.